Health Feed
US$ 29.63
bcbs federal glp 1 coverage Blue Cross Blue Shield plans reverse course on GLP-1 Does Blue Cross Blue Shield
Description
Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)
The challenge remains that prior to treatment initiation it remains virtually impossible to predict who will have side effects (3)
Schedule a consultation with the Dwell team
C., and Phillips, S
